Through an extensive array of ex vivo human tissue assays, Biopta is able to provide invaluable human safety data for your compound early in the development cycle.
The benefits of undertaking safety testing in human tissues are many. When carried out in conjunction with the ICH S7A core battery, our data can provide an unparalleled indication of clinical safety and even reduce the number of animals required for in vivo experimentation. More importantly though, our data can help reduce the number of late stage failures as ‘go’ or ‘no go’ decisions can be made with confidence based on human responses. In addition to the positive effect on cost and time to clinic, human safety data adds significant value for investors and potential partners.